SCHEMBL2157624

SCHEMBL2157624

Cc1cc(Cl)ccc1S(=O)(=O)Nc1csc(-c2ccccc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.49
IDH1 O75874 5/20 0.45
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM1A O60341 1/20 0.44
MAOA P21397 1/20 0.44
TRIM24 O15164 1/20 0.43
BRD1 O95696 1/20 0.43
BRPF1 P55201 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
PGR P06401 1/20 0.43
ITGA1 P56199 1/20 0.43
PTGES2 Q9H7Z7 1/20 0.43
CDK1 P06493 1/20 0.42
CCNB1 P14635 1/20 0.42
CCNA2 P20248 1/20 0.42
CDK2 P24941 1/20 0.42
CDK7 P50613 1/20 0.42
CCNH P51946 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2158176 0.88 ALDH1A1 (0.52) MEN1POLBKMT2ABRPF1
SCHEMBL2158700 0.88 ITGA1 (0.56) CNR1MEN1POLBKMT2AKDM1A
SCHEMBL2157826 0.87 KDM1A (0.48) CNR1IDH1MEN1KMT2AKDM1A
SCHEMBL2157979 0.86 KDM1A (0.59) CNR1IDH1KDM1AMAOA
SCHEMBL2158433 0.85 RXFP1 (0.48) MEN1POLBKMT2A
SCHEMBL2157816 0.85 CA1 (0.44) CNR1POLBKMT2ABRD1BRPF1
SCHEMBL2157528 0.81 PFKFB3 (0.52) CNR1MEN1POLBKMT2APGR
SCHEMBL2158054 0.80 ALDH1A1 (0.52) IDH1MEN1KMT2A
SCHEMBL2158510 0.79 LMNA (0.45) CNR1MEN1POLBKMT2A
SCHEMBL2157552 0.79 KDM1A (0.47) IDH1POLBKDM1AMAOAITGA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985769-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-26 US disclosed
US-20060142347-A1 Compounds and methods for the treatment or prevention of Flavivirus infections VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) 2006-06-29 US disclosed
US-6881741-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VIROCHEM PHARMA INC. (CA) 2005-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142347-A1 Compounds and methods for the treatment or prevention of Flavivirus infections HAVCR2, ZC3HAV1, MAVS CNR1 3333/4885IDH1 791/4885MEN1 3052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.